Table 1.
Comparison of patient’s characteristics between CIA and non-CIA in the subgroup of patients treated with chemotherapy without OST
| N (total)=252 | CIA (−) n (%) | CIA (+) n (%) | p |
|---|---|---|---|
| age (years) | |||
| ≤35 n =50 | 38 (35.5%) | 12 (8.3%)/ | |
| >35 n=202 | 69 (64.5%) | 133 (91.7 %) | p<0.001 |
| Molecular subtype | |||
| Luminal A n=80 | 28 (26.2 %) | 52 (35.8 %) | |
| Luminal B n=99 | 41 (38.3%) | 58 (40 %) | |
| Her 2 (+) n=26 | 11 (10.3%) | 15 (10.3%) | |
| Triple (−) n=48 | 27 (25.2%) | 21 (14.4%) | p<0.001 |
| Surgery | |||
| BCS n=163 | 75(70.1%) | 88 (60.6%) | |
| MRM) n=89 | 32 (29.9%) | 57 (39.4%) | p=0.113 |
| LVI (−) n=120 | 52 (48.6%)/ | 68 (47.9%)/ | |
| LVI (+) n=132 | 55 (51.4%) | 77 (53.1%) | P=0.829 |
| Multicentricity/multifocality | |||
| None n=181 | 74 (69.2%)/ | 107 (73.8%)/ | |
| Yes n=71 | 33 (31.8%) | 38 (26.2%) | p=0.419 |
| Axillary dissection | |||
| None n=95 | 49 (45.8%)/ | 46 (31.7%)/ | |
| Yes n=157 | 58 (54.2%) | 99 (68.3%) | p=0.023 |
| HER - 2 | |||
| Negative n=186 | 77 (73.3%)/ | 109 (75.2%)/ | |
| Positive n=66 | 30 (26.7%) | 36 (24.8%) | p=0.722 |
| HR | |||
| Positive n=186 | 74 (71.8%)/ | 112 (78.2%)/ | |
| Negative n=66 | 33 (28.2%) | 33 (22.8%) | p=0.026 |
| CT | |||
| Taxane (+) n=114 | 45 (42.1%)/ | 69 (48.3%)/ | |
| Taxane (−) n=138 | 62 (57.9%) | 76 (51.7%) | p=0.330 |
| RT | |||
| No n=26 | 8 (7.5%)/ | 18 (12.4%)/ | |
| Yes n=226 | 99 (82.5%) | 127 (87.6 %) | p=0.203 |
| Pathological stage | |||
| 1 n=68 | 31(29%)/ | 37 (25.5%)/ | |
| 2+3 n=184 | 76 (71%) | 108 (74.5%) | p=0.541 |
| Histological Grade | |||
| 1/n= 84 | 23 (21.5%)/ | 61 (42.1%)/ | |
| 2+3 n=168 | 84(78.5%) | 84 (57.9%) | p=0.001 |
| Lymph Node | |||
| Positive n=123 | 58 (54.2%)/ | 65 (44.8%)/ | |
| Negative n=129 | 49 (45.8%) | 80 (55.2%) | p=0.141 |
OA: over ablation; CT: chemotherapy; LVI: lymphovascular invasion; RT: radiotherapy